MD Anderson Cancer Ctr. Gynecology SPORE: Uterine Cancer

描述(申请人提供)：德克萨斯大学安德森癌症中心妇科癌症孢子中心的目标是为子宫肿瘤的预防和治疗进行创新的转化研究。起源于子宫上皮(子宫内膜)和子宫肌层(肌层)的肿瘤是美国发病率和死亡率的重要原因，但资金不足。子宫内膜癌是美国最常见的妇科恶性肿瘤，2002年估计有39,300例新病例和6,600例死亡。子宫平滑肌肿瘤，特别是子宫肌瘤，是美国最常见的子宫切除术适应症，估计每年有25万例子宫切除术可归因于这些肿瘤。 拟议的妇科癌症孢子是一个真正的多学科计划，包括具有肿瘤学和非肿瘤学背景的临床医生和基础科学家。为了更彻底地了解这些肿瘤的发病机制、预防和治疗，这样一个多学科的团队是必要的。妇科孢子由五个研究项目组成：项目1，晚期或复发子宫内膜腺癌患者的Arzoxifene和Megace与旨在确定作用机制的实验室相关性的随机第二阶段比较(Thomas Burke，M.D.和Cheryl Walker，Ph.D.，共同首席研究员)。项目2，肥胖妇女的新的子宫内膜癌化学预防策略，高危人群(Karen Lu，M.D.，Peter Davies，M.D.，Ph.D.，共同首席研究员)。项目3，子宫内膜癌的CpG岛甲基化分析(Russell Broaddus，M.D.，Ph.D.，Jean-Pierre Issa，M.D.，共同首席调查员)。项目4，子宫内膜癌的分子进展(David Lose-Mitchell，Ph.D.和Judith Wolf，M.D.，共同首席研究员)。这些研究项目得到四个核心的支持：核心1，行政(Thomas Burke，M.D.，首席调查员)；核心2，病理学(Russell Broaddus，M.D.，Ph.D.，首席调查员)；核心3，Biomarkers(David Lose-Mitchell，博士，首席调查员)；以及核心4，生物统计学和生物信息学(Peter Mueller，博士，首席调查员)。发展研究计划(谢丽尔·沃克博士，首席研究员)将为创新研究提供资金。职业发展计划(乔治·斯坦塞尔博士，首席研究员)将鼓励教师发展研究。内部咨询委员会和外部咨询委员会将协助对项目进行科学和临床规划和评价。

DESCRIPTION (provided by applicant): The goal of the Gynecological Cancer SPORE at the University of Texas - M.D. Anderson Cancer Center is to conduct innovative translational research for the prevention and treatment of uterine tumors. Tumors arising from the epithelial (endometrium) and smooth muscle (myometrium) compartments of the uterus are important, yet under- funded, causes of morbidity and mortality in the United States. Endometrial cancer is the most common gynecological malignancy in the United States with an estimated 39,300 new cases and 6,600 deaths for 2002. Smooth muscle tumors of the uterus, especially leiomyomas, are the most common indication for hysterectomy in the United States, with an estimated 250,000 hysterectomies per year attributable to these tumors. The proposed Gynecological Cancer SPORE is a truly multidisciplinary program that includes clinicians and basic scientists with both oncologic and non-oncologic backgrounds. Such a multidisciplinary team is necessary to achieve a more thorough understanding of the pathogenesis, prevention, and treatment of these tumors. The Gynecologic SPORE consists of five research projects: Project 1, Randomized Phase II Comparison of Arzoxifene and Megace in Women with Advanced or Recurrent Endometrial Adenocarcinoma with Laboratory Correlates Designed to Identify Mechanism of Action (Thomas Burke, M.D., and Cheryl Walker, Ph.D., Co-Principal lnvestigator). Project 2, A Novel Endometrial Cancer Chemoprevention Strategy for Obese Women, an At-Risk Population (Karen Lu, M.D., and Peter Davies, M.D., Ph.D., Co-Principal Investigators). Project 3, CpG Island Methylation Profiling of Endometrial Cancer (Russell Broaddus, M.D., Ph.D., and Jean-Pierre Issa, M.D., Co-Principal lnvestigators). Project 4, Molecular Progression of Endometrial Cancer (David Loose-Mitchell, Ph.D., and Judith Wolf, M.D., Co-Principal Investigators). The research projects are supported by four cores: Core 1, Administration (Thomas Burke, M.D., Principal Investigators); Core 2, Pathology (Russell Broaddus, M.D., Ph.D., Principal Investigators); Core 3, Biomarkers (David Loose-Mitchell, Ph.D., Principal Investigator); and Core 4, Biostatistics and Bioinformatics (Peter Mueller, Ph.D., Principal Investigator). The Developmental Research Program (Cheryl Walker, Ph.D., Principal Investigator) will provide funding for innovative research. A Career Development Program (George Stancel, Ph.D., Principal Investigator) will encourage faculty development research. An Internal Advisory Committee and External Advisory Committee will assist in scientific and clinical planning and evaluation of projects.